...
首页> 外文期刊>Bone marrow transplantation >Leaving previously implanted central venous catheters (ports) in place does not increase morbidity in patients undergoing autologous peripheral stem cell transplantation.
【24h】

Leaving previously implanted central venous catheters (ports) in place does not increase morbidity in patients undergoing autologous peripheral stem cell transplantation.

机译:在进行自体外周干细胞移植的患者中,将先前植入的中央静脉导管(端口)留在原位不会增加发病率。

获取原文
获取原文并翻译 | 示例

摘要

We sought to assess if leaving in place a previously inserted noncolonized or infected implantable catheter (IC) is associated with an increase in morbidity in patients undergoing autologous peripheral stem cell transplantation (APSCT). Medical records from all patients between March 1997 and January 2002 undergoing APSCT with an IC in place were reviewed. Case group (IC in place) was compared with a control group (no IC) from 6 days prior to 60 days after APSCT. In all, 43 cases were matched with 43 controls by underlying disease, age and sex. In both groups, duration of neutropenia and use of antimicrobial prophylaxis were comparable. Underlying malignancies were lymphoma (22/24), multiple myeloma (14/12), leukemia (3/3), and others (7/7) in case and control groups. Cases and controls had comparable rates of risk for fever, bloodstream infection, use of vancomycin and amphotericin B, and death, as well as comparable lengths of stay and readmissions. ICs were used in 20 of 43 patients. Using the IC did not significantly increase the risk of fever, bloodstream infection, length of stay, and/or readmissions after APSCT but was associated with increased use of antibacterial and antifungal agents. Leaving in place a previously inserted, noncolonized or infected IC did not increase morbidity in patients undergoing APSCT.
机译:我们试图评估在接受自体外周干细胞移植(APSCT)的患者中,先前插入的未克隆或感染的可植入导管(IC)是否留在原位是否与发病率增加相关。回顾了1997年3月至2002年1月期间所有接受APSCT并已安装IC的患者的病历。将APSCT后60天至6天的病例组(就位IC)与对照组(无IC)进行比较。根据潜在疾病,年龄和性别,总共有43例与43例对照相匹配。在两组中,中性粒细胞减少症的持续时间和使用抗菌药物的预防措施均具有可比性。在病例组和对照组中,潜在的恶性肿瘤为淋巴瘤(22/24),多发性骨髓瘤(14/12),白血病(3/3)和其他(7/7)。病例和对照的发烧,血液感染,使用万古霉素和两性霉素B以及死亡的风险率相当,并且住院和再入院的时间也相当。 IC被用于43位患者中的20位。使用IC不会显着增加APSCT后发烧,血液感染,住院时间和/或再入院的风险,但与增加使用抗菌药和抗真菌药有关。将先前插入的,未克隆或感染的IC留在原位不会增加APSCT患者的发病率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号